NCT05940051View on ClinicalTrials.gov

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

July 1, 2025

Study Completion Date

December 30, 2025

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

Zanubrutinib, Polatuzumab vedotin and Rituximab

Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m2 ivgtt D1

Trial Locations (1)

200032

RECRUITING

Zhongshan Hospital，Fudan University, Shanghai

All Listed Sponsors
lead

Peng Liu

OTHER